Clinical trials: Allergy; Dermatitis
Atopic Dermatitis
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.
- Trial name
- NCT05614817
- Testing
- CBP-201
- Sponsor
- Connect Biopharm LLC
Conjunctivitis, Atopic Dermatitis
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during…
- Trial name
- NCT04287608
- Testing
- dupilumab
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis
This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from…
- Trial name
- NCT05644691
- Testing
- Lipikar Baume AP+M, Usual emollient
- Where
- Slovakia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Atopic Dermatitis
Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
This is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with…
- Trial name
- NCT04564755
- Testing
- abrocitinib
- Where
- 57 sites in United States, Australia and 10 more
- Sponsor
- Pfizer
Photoallergy
To Test for Photo Allergy Reaction of Sunscreens
The primary objective of this tudy was to evaluate the potential of photoallergy of of sun care products Sun Protection Factor (SPF) 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 application compared to that of a negative…
- Trial name
- NCT02872220
- Testing
- SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Atopic Dermatitis (AD)
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of…
- Trial name
- MG-K10 (NCT07103174)
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion in Adults of Atopic Dermatitis.
This study will evaluate the safety and efficacy of a moisturizer body lotion: the study aims to determine the tolerance of this product by the study population, and its effects on atopic dermatitis condition, skin hydration…
- Trial name
- NCT05062213
- Testing
- Moisturizer Body Lotion
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis
Study to Evaluate the Use of a Probiotic in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that an oral probiotic treatment reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 4 to 17 years, as compared to placebo.
- Trial name
- NCT03822624
- Testing
- Probiotic
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Biopolis S.L.
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.
Atopic Dermatitis
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such…
- Trial name
- ADVANTA (NCT06058156)
- Testing
- SAR444656 (KT-474)
- Where
- 37 sites in United States, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis
- Trial name
- NCT05526222
- Testing
- Jaktinib Hydrochloride Tablet
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD7 (NCT03733301)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 68 sites in Argentina, Australia and 8 more
- Volunteers
- 329 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis (Eczema)
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
- Trial name
- NCT06998056
- Testing
- ARQ-151 cream 0.05%
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 101 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis, Eczema
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis.
- Trial name
- ADAIR (NCT05689151)
- Testing
- Abrocitinib
- Where
- 30 sites in France
- Volunteers
- 183 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product
1. Curing mild atopic dermatis in children with a commerical medical device (Bepanthen Itch Relief Cream). 2. Maintaining healthy skin by using a new cosmetic Bepanthen product or a commercially available cosmetic product
- Trial name
- NCT02615561
- Testing
- Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543), New cosmetic Bepanthen product: Pumpkin (BAY207543), Stelatopia (cosmetic comparator)
- Where
- 14 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Bayer
Atopic Dermatitis, Neurodermatitis
Investigation of Efficacy and Safety of EPOGAM
In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.
- Trial name
- NCT00878670
- Testing
- EPOGAM 1000
- Where
- 2 sites in Switzerland
- Volunteers
- 23 people
- Sponsor
- Max Zeller Soehne AG
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.